Protalix BioTherapeutics Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Dror Bashan

Chief Executive Officer (CEO)

US$2.7m

Compensación total

Porcentaje del salario del CEO	13.3%
Permanencia del CEO	5yrs
Participación del CEO	3.1%
Permanencia media de la dirección	4.9yrs
Promedio de permanencia en la Junta Directiva	4.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dror Bashan en comparación con los beneficios de Protalix BioTherapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$7m
Dec 31 2023	US$3m	US$357k	US$8m
Sep 30 2023	n/a	n/a	US$11m
Jun 30 2023	n/a	n/a	US$9m
Mar 31 2023	n/a	n/a	-US$16m
Dec 31 2022	US$1m	US$360k	-US$15m
Sep 30 2022	n/a	n/a	-US$18m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$24m
Dec 31 2021	US$1m	US$374k	-US$28m
Sep 30 2021	n/a	n/a	-US$21m
Jun 30 2021	n/a	n/a	-US$21m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$1m	US$352k	-US$7m
Sep 30 2020	n/a	n/a	-US$7m
Jun 30 2020	n/a	n/a	-US$6m
Mar 31 2020	n/a	n/a	-US$9m
Dec 31 2019	US$566k	US$175k	-US$18m

Compensación vs. Mercado: La compensación total de Dror($USD2.68M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD419.73K).

Compensación vs. Ingresos: La compensación de Dror ha sido consistente con los resultados de la empresa en el último año.

CEO

Dror Bashan (57 yo)

5yrs

Permanencia

US$2,684,941

Compensación

Mr. Dror Bashan has been President, Chief Executive Officer and Director of Protalix BioTherapeutics, Inc. since June 30, 2019. He has experience in the pharmaceutical industry with roles ranging from busi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Dror Bashan	President	5yrs	US$2.68m	3.11% $ 2.4m
Eyal Rubin	Senior VP	4.8yrs	US$1.03m	0.78% $ 607.1k
Yaron Naos	Senior Vice President of Operations	6.1yrs	US$776.37k	0.28% $ 220.8k
Yael Fellous	Vice President of Human Resources	1.8yrs	sin datos	sin datos

4.9yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de PBDA se considera experimentado (4.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Dror Bashan	President	5yrs	US$2.68m	3.11% $ 2.4m
Amos Shalev	Independent Director	15.9yrs	US$79.91k	0.00023% $ 179.6
Aharon Schwartz	Independent Director	9.6yrs	US$79.91k	0.24% $ 185.3k
Gwen A. Melincoff	Independent Director	4.4yrs	US$79.91k	sin datos
Charles Arntzen	Member of Scientific Advisory Board	8yrs	sin datos	sin datos
Alexander Levitzki	Member of Scientific Advisory Board	no data	sin datos	sin datos
Shmuel Ben-Zvi	Independent Director	2yrs	US$74.71k	sin datos
Roger Kornberg	Chairman of Scientific Advisory Board	no data	US$55.00k	sin datos
Eliot Forster	Independent Chairman	less than a year	US$47.99k	sin datos
Pol Boudes	Independent Director	4.4yrs	US$115.39k	0.000050% $ 39.0

4.7yrs

Permanencia media

71.5yo

Promedio de edad

Junta con experiencia: La junta directiva de PBDA se considera experimentada (4.7 años de antigüedad promedio).

Protalix BioTherapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Protalix BioTherapeutics, Inc., Annual General Meeting, Jun 27, 2024

Protalix Biotherapeutics Appoints Eliot Richard Forster to Succeed Zeev Bronfeld as Chairman, Effective as of September 14, 2023

Protalix BioTherapeutics, Inc., Annual General Meeting, Jun 28, 2023

Protalix BioTherapeutics, Inc. Appoints Shmuel "Muli" Ben Zvi to Its Board of Directors and Audit Committee and Compensation Committee

President recently bought €94k worth of stock

Recent updates

Protalix BioTherapeutics, Inc. to Report Q1, 2024 Results on May 10, 2024

Protalix BioTherapeutics, Inc., Annual General Meeting, Jun 27, 2024

Protalix BioTherapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Protalix BioTherapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Protalix Biotherapeutics Appoints Eliot Richard Forster to Succeed Zeev Bronfeld as Chairman, Effective as of September 14, 2023

Protalix BioTherapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Protalix BioTherapeutics, Inc., Annual General Meeting, Jun 28, 2023

Chiesi Global Rare Diseases and Protalix Biotherapeutics, Inc. Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease

Protalix Biotherapeutics, Inc. and Chiesi Global Rare Diseases Announces European Commission Grants Marketing Authorization to PRX-102 (Pegunigalsidase Alfa) for the Treatment of Adult Patients with Fabry Disease

Protalix BioTherapeutics to Delist Its Common Stock from the Tel Aviv Stock Exchange

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of A Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Third quarter 2022 earnings released: US$0.072 loss per share (vs US$0.092 loss in 3Q 2021)

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.25 loss in 2Q 2021)

Protalix BioTherapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Protalix BioTherapeutics, Inc. Appoints Shmuel "Muli" Ben Zvi to Its Board of Directors and Audit Committee and Compensation Committee

First quarter 2022 earnings released: US$0.05 loss per share (vs US$0.14 loss in 1Q 2021)

Protalix BioTherapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

President recently bought €94k worth of stock

Protalix Biotherapeutics, Inc. Announces Topline Results from BALANCE Pivotal Phase III Clinical Trial Evaluating pegunigalsidase alfa

Full year 2021 earnings released: US$0.63 loss per share (vs US$0.22 loss in FY 2020)

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Submission of Marketing Authorization Application to the European Medicines Agency for PRX-102 for Treatment of Fabry Disease

Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.14 loss in 3Q 2020)

Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.14 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.13 loss in 2Q 2020)

Protalix BioTherapeutics, Inc. Announces Submission of Type A Meeting Request to the FDA

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease

Forecast breakeven pushed back to 2022

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.096 profit in 1Q 2020)

Protalix Biotherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from Fda

Full year 2020 earnings released: US$0.22 loss per share (vs US$1.23 loss in FY 2019)

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Positive Topline Results from Bright Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 Mg/Kg Every Four Weeks for Treatment of Fabry Disease

Protalix Biotherapeutics Enters into an Exclusive Partnership with Sarcomed USA to Develop Alidornase Alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery

Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021

New 90-day high: €3.74

Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021

New 90-day high: €3.44

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Results of Bridge Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announces Extension of Pdufa Date for Pegunigalsidase Alfa for the Propose Treatment of Fabry Disease

Third quarter earnings released

New 90-day low: €2.76

Chiesi Farmaceutici S.P.A. and Protalix BioTherapeutics, Inc Announce Launch of an Expanded Access Program (Eap) in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Protalix Biotherapeutics and Chiesi Farmaceutici Announce Successful Pre-BLA Meeting with FDA for Accelerated Approval of Pegunigalsidase Alfa for the Treatment of Fabry Disease in the United States

New 90-day low - €2.82

Protalix Biotherapeutics Regains Compliance with NYSE American Continued Listing Standards

New 90-day low - €2.88

First half earnings released

Protalix BioTherapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad